1887

Chapter 53 : Arthropod-Borne Flaviviruses

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Arthropod-Borne Flaviviruses, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819439/9781555819422.ch53-1.gif /docserver/preview/fulltext/10.1128/9781555819439/9781555819422.ch53-2.gif

Abstract:

In 1901 the prototype flavivirus disease, yellow fever, was the first human illness shown to be caused by a filterable virus, and, in 1927, it became the first member of the flavivirus family to be isolated. The derive their name from yellow ( Latin) fever. From the medical perspective, the flaviviruses are the most important group of arthropod-borne viruses (arboviruses). Dengue fever and dengue hemorrhagic fever (DHF) are major causes of human morbidity worldwide. Yellow fever remains an epidemic threat in Africa and South America. Since its introduction into North America, West Nile virus (WNV) has caused annual outbreaks of encephalitis and febrile illness in North America and has spread throughout the Americas as far south as Argentina; Japanese encephalitis (JE) remains a major cause of viral encephalitis in Asia.

Citation: Petersen L, Barrett A. 2017. Arthropod-Borne Flaviviruses, p 1267-1311. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch53
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Geographical distribution of JE.

Citation: Petersen L, Barrett A. 2017. Arthropod-Borne Flaviviruses, p 1267-1311. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch53
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

Transmission cycle of JE virus. Broken lines indicate speculative portions of the transmission cycle.

Citation: Petersen L, Barrett A. 2017. Arthropod-Borne Flaviviruses, p 1267-1311. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch53
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3
FIGURE 3

SLE neuroinvasive disease cases by state, 2004–2013.

Citation: Petersen L, Barrett A. 2017. Arthropod-Borne Flaviviruses, p 1267-1311. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch53
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 4
FIGURE 4

Transmission cycle of SLE virus and WNV. Both viruses are transmitted in a cycle between birds and Culex mosquitoes. is an important vector in the northern United States and Canada. is important in the southern United States, whereas is important in the western United States. In addition, is a vector in Florida. Other mosquito species may be “bridge” vectors to horses, humans, and other dead-end hosts, which typically do not develop high-level viremia and do not participate in the transmission cycle. However, bridge vectors likely have a minor role compared to enzootic vectors in viral transmission to dead-end hosts.

Citation: Petersen L, Barrett A. 2017. Arthropod-Borne Flaviviruses, p 1267-1311. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch53
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 5
FIGURE 5

Number of reported cases of SLE, 1932–2012.

Citation: Petersen L, Barrett A. 2017. Arthropod-Borne Flaviviruses, p 1267-1311. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch53
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 6
FIGURE 6

Geographical distribution of TBE.

Citation: Petersen L, Barrett A. 2017. Arthropod-Borne Flaviviruses, p 1267-1311. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch53
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 7
FIGURE 7

Transmission cycle of TBE. Reprinted with permission from T. P. Monath and E. X. Heinz. 1996. Flaviviruses, page 994. In B. N. Fields, D. M. Knipe, and P. M. Howley (eds.), , third edition. Lippincott-Raven, Philadelphia, PA.

Citation: Petersen L, Barrett A. 2017. Arthropod-Borne Flaviviruses, p 1267-1311. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch53
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 8
FIGURE 8

Expansion of WNV in North America, Central America, and the Caribbean, 1999 to 2006. Areas demarcated by solid lines confirmed by virological confirmation in mosquitoes or vertebrates. Areas demarcated by dashed lines are those with serological evidence in vertebrates only. Serological evidence of WNV was found in Colombia and Venezuela in 2004, and WNV caused an equine outbreak in Argentina in 2006.

Citation: Petersen L, Barrett A. 2017. Arthropod-Borne Flaviviruses, p 1267-1311. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch53
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 9
FIGURE 9

Geographical risk map of dengue fever.

Citation: Petersen L, Barrett A. 2017. Arthropod-Borne Flaviviruses, p 1267-1311. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch53
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 10
FIGURE 10

Simplified transmission cycle of dengue and yellow fever viruses. Both viruses have a jungle cycle involving tree-hole mosquitoes. In the Americas, sp. transmits yellow fever, but no jungle cycle for dengue has been discovered. In Africa, both viruses are transmitted in jungle cycles involving spp. Yellow fever does not exist in Asia, but in Malaysia, Sri Lanka, and probably elsewhere, dengue virus is transmitted in a jungle cycle involving spp. The relationship between the jungle cycle of dengue and human infections is not clear. However, the jungle cycle of yellow fever is a source of human infections in the Americas and Africa. Dengue transmission occurs principally in urban environments, where domestic serves as the vector and humans serve as the viremic host. A similar cycle of yellow fever transmission occurs commonly in West Africa. No urban outbreaks of yellow fever have occurred in the Americas since 1964, except possibly for a very limited outbreak in Bolivia in 1997 to 1998.

Citation: Petersen L, Barrett A. 2017. Arthropod-Borne Flaviviruses, p 1267-1311. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch53
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 11
FIGURE 11

Geographical distribution of yellow fever.

Citation: Petersen L, Barrett A. 2017. Arthropod-Borne Flaviviruses, p 1267-1311. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch53
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819439.ch53
1. Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, Brandt WE. 1989. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 70:3743.[PubMed]
2. Cook S, Moureau G, Kitchen A, Gould EA, de Lamballerie X, Holmes EC, Harbach RE. 2012. Molecular evolution of the insect-specific flaviviruses. J Gen Virol 93:223234.[PubMed]
3. Grard G, Moureau G, Charrel RN, Lemasson JJ, Gonzalez JP, Gallian P, Gritsun TS, Holmes EC, Gould EA, de Lamballerie X. 2007. Genetic characterization of tick-borne flaviviruses: new insights into evolution, pathogenetic determinants and taxonomy. Virology 361:8092.[PubMed]
4. Holmes EC, Worobey M, Rambaut A. 1999. Phylogenetic evidence for recombination in dengue virus. Mol Biol Evol 16:405409.[PubMed]
5. Zanotto PM, Gould EA, Gao GF, Harvey PH, Holmes EC. 1996. Population dynamics of flaviviruses revealed by molecular phylogenies. Proc Natl Acad Sci USA 93:548553.[PubMed]
6. Chambers TJ, Hahn CS, Galler R, Rice CM. 1990. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44:649688.[PubMed]
7. Halstead SB, O'Rourke EJ. 1977. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146:201217.[PubMed]
8. Peiris JS, Porterfield JS. 1979. Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. Nature 282:509511.[PubMed]
9. Halstead SB. 2014. Dengue antibody-dependent enhancement: knowns and unknowns. microbiolspec 2(6)[CrossRef].[PubMed]
10. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375:291298.[PubMed]
11. Corver J, Ortiz A, Allison SL, Schalich J, Heinz FX, Wilschut J. 2000. Membrane fusion activity of tick-borne encephalitis virus and recombinant subviral particles in a liposomal model system. Virology 269:3746.[PubMed]
12. Jacobs MG, Robinson PJ, Bletchly C, Mackenzie JM, Young PR. 2000. Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction. FASEB J 14:16031610.[PubMed]
13. Schlesinger JJ, Brandriss MW, Putnak JR, Walsh EE. 1990. Cell surface expression of yellow fever virus non-structural glycoprotein NS1: consequences of interaction with antibody. J Gen Virol 71:593599.[PubMed]
14. Mathew A, Kurane I, Rothman AL, Zeng LL, Brinton MA, Ennis FA. 1996. Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J Clin Invest 98:16841691.[PubMed]
15. Muñoz-Jordan JL, Sánchez-Burgos GG, Laurent-Rolle M, García-Sastre A. 2003. Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci USA 100:1433314338.[PubMed]
16. Kuno G. 2007. Host range specificity of flaviviruses: correlation with in vitro replication. J Med Entomol 44:93101.[PubMed]
17. Weaver SC, Barrett AD. 2004. Transmission cycles, host range, evolution and emergence of arboviral disease. Nat Rev Microbiol 2:789801.[PubMed]
18. Nuttall PA. 1999. Pathogen-tick-host interactions: borrelia burgdorferi and TBE virus. Zentralbl Bakteriol 289:492505.[PubMed]
19. Meier KC, Gardner CL, Khoretonenko MV, Klimstra WB, Ryman KD. 2009. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog 5:e1000614.[PubMed]
20. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. 2006. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80:1020810217.[PubMed]
21. Milligan GN, Sarathy VV, Infante E, Li L, Campbell GA, Beatty PR, Harris E, Barrett AD, Bourne N. 2015. A dengue virus type 4 model of disseminated lethal infection in AG129 mice. PLoS One 10:e0125476.[PubMed]
22. Sarathy VV, White M, Li L, Gorder SR, Pyles RB, Campbell GA, Milligan GN, Bourne N, Barrett AD. 2015. A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease. J Virol 89:12541266.[PubMed]
23. Garcia-Tapia D, Hassett DE, Mitchell WJ Jr, Johnson GC, Kleiboeker SB. 2007. West Nile virus encephalitis: sequential histopathological and immunological events in a murine model of infection. J Neurovirol 13:130138.[PubMed]
24. Johnston LJ, Halliday GM, King NJ. 2000. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. J Invest Dermatol 114:560568.[PubMed]
25. Chambers TJ, Diamond MS. 2003. Pathogenesis of flavivirus encephalitis. Adv Virus Res 60:273342.[PubMed]
26. Schneider BS, Soong L, Girard YA, Campbell G, Mason P, Higgs S. 2006. Potentiation of West Nile encephalitis by mosquito feeding. Viral Immunol 19:7482.[PubMed]
27. King NJ, Getts DR, Getts MT, Rana S, Shrestha B, Kesson AM. 2007. Immunopathology of flavivirus infections. Immunol Cell Biol 85:3342.[PubMed]
28. Ben-Nathan D, Kobiler D, Rzotkiewicz S, Lustig S, Katz Y. 2000. CNS penetration by noninvasive viruses following inhalational anesthetics. Ann N Y Acad Sci 917:944950.[PubMed]
29. Wang P, Bai F, Zenewicz LA, Dai J, Gate D, Cheng G, Yang L, Qian F, Yuan X, Montgomery RR, Flavell RA, Town T, Fikrig E. 2012. IL-22 signaling contributes to West Nile encephalitis pathogenesis. PLoS One 7:e44153.[PubMed]
30. Donadieu E, Bahuon C, Lowenski S, Zientara S, Coulpier M, Lecollinet S. 2013. Differential virulence and pathogenesis of West Nile viruses. Viruses 5:28562880.[PubMed]
31. Klein RS, Diamond MS. 2008. Immunological headgear: antiviral immune responses protect against neuroinvasive West Nile virus. Trends Mol Med 14:286294.[PubMed]
32. Hunsperger EA, Roehrig JT. 2006. Temporal analyses of the neuropathogenesis of a West Nile virus infection in mice. J Neurovirol 12:129139.[PubMed]
33. Kuno G. 2001. Persistence of arboviruses and antiviral antibodies in vertebrate hosts: its occurrence and impacts. Rev Med Virol 11:165190.[PubMed]
34. Shellam GR, Sangster MY, Urosevic N. 1998. Genetic control of host resistance to flavivirus infection in animals. Rev Sci Tech 17:231248.[PubMed]
35. Perelygin AA, Scherbik SV, Zhulin IB, Stockman BM, Li Y, Brinton MA. 2002. Positional cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci USA 99:93229327.[PubMed]
36. Yakub I, Lillibridge KM, Moran A, Gonzalez OY, Belmont J, Gibbs RA, Tweardy DJ. 2005. Single nucleotide polymorphisms in genes for 2′-5′-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J Infect Dis 192:17411748.[PubMed]
37. Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM. 2006. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203:3540.[PubMed]
38. Diamond MS, Klein RS. 2006. A genetic basis for human susceptibility to West Nile virus. Trends Microbiol 14:287289.[PubMed]
39. Suthar MS, Diamond MS, Gale M Jr. 2013. West Nile virus infection and immunity. Nat Rev Microbiol 11:115128.[PubMed]
40. Green AM, Beatty PR, Hadjilaou A, Harris E. 2014. Innate immunity to dengue virus infection and subversion of antiviral responses. J Mol Biol 426:11481160.[PubMed]
41. Lazear HM, Diamond MS. 2015. New insights into innate immune restriction of West Nile virus infection. Curr Opin Virol 11:16.[PubMed]
42. Liu Y, King N, Kesson A, Blanden RV, Müllbacher A. 1989. Flavivirus infection up-regulates the expression of class I and class II major histocompatibility antigens on and enhances T cell recognition of astrocytes in vitro. J Neuroimmunol 21:157168.[PubMed]
43. Broom AK, Wallace MJ, Mackenzie JS, Smith DW, Hall RA. 2000. Immunisation with gamma globulin to murray valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against australian encephalitis: evaluation in a mouse model. J Med Virol 61:259265.[PubMed]
44. Gould EA, Buckley A. 1989. Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J Gen Virol 70:16051608.[PubMed]
45. Andrews DM, Matthews VB, Sammels LM, Carrello AC, McMinn PC. 1999. The severity of murray valley encephalitis in mice is linked to neutrophil infiltration and inducible nitric oxide synthase activity in the central nervous system. J Virol 73:87818790.[PubMed]
46. Pang T, Cardosa MJ, Guzman MG. 2007. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever–dengue shock syndrome (DHF/DSS). Immunol Cell Biol 85:4345.[PubMed]
47. Huang YH, Chang BI, Lei HY, Liu HS, Liu CC, Wu HL, Yeh TM. 1997. Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity. Clin Exp Immunol 110:3540.[PubMed]
48. McMinn PC. 1997. The molecular basis of virulence of the encephalitogenic flaviviruses. J Gen Virol 78:27112722.[PubMed]
49. Wu SC, Lian WC, Hsu LC, Liau MY. 1997. Japanese encephalitis virus antigenic variants with characteristic differences in neutralization resistance and mouse virulence. Virus Res 51:173181.[PubMed]
50. Tsarev SA, Sanders ML, Vaughn DW, Innis BL. 2000. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. Vaccine 18(Suppl 2):3643.[PubMed]
51. Schuh AJ, Ward MJ, Leigh Brown AJ, Barrett AD. 2014. Dynamics of the emergence and establishment of a newly dominant genotype of Japanese encephalitis virus throughout Asia. J Virol 88:45224532.[PubMed]
52. Kim H, Cha GW, Jeong YE, Lee WG, Chang KS, Roh JY, Yang SC, Park MY, Park C, Shin EH. 2015. Detection of Japanese encephalitis virus genotype V in Culex orientalis and Culex pipiens (Diptera: Culicidae) in Korea. PLoS One 10:e0116547.[PubMed]
53. Li MH, Fu SH, Chen WX, Wang HY, Guo YH, Liu QY, Li YX, Luo HM, Da W, Duo Ji DZ, Ye XM, Liang GD. 2011. Genotype v Japanese encephalitis virus is emerging. PLoS Negl Trop Dis 5:e1231.[PubMed]
54. Mohammed MA, Galbraith SE, Radford AD, Dove W, Takasaki T, Kurane I, Solomon T. 2011. Molecular phylogenetic and evolutionary analyses of Muar strain of Japanese encephalitis virus reveal it is the missing fifth genotype. Infect Genet Evol 11:855862.[PubMed]
55. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS. 2011. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 89:766774, 774A-774E.
56. Vaughn DW, Hoke CH Jr. 1992. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev 14:197221.[PubMed]
57. Grossman RA, Edelman R, Chiewanich P, Voodhikul P, Siriwan C. 1973. Study of Japanese encephalitis virus in Chiangmai valley, Thailand. II. Human clinical infections. Am J Epidemiol 98:121132.[PubMed]
58. Desai A, Ravi V, Chandramuki A, Gourie-Devi M. 1995. Proliferative response of human peripheral blood mononuclear cells to Japanese encephalitis virus. Microbiol Immunol 39:269273.[PubMed]
59. Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, Koli P, Sen E, Basu A. 2007. Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 55:483496.[PubMed]
60. Rayamajhi A, Singh R, Prasad R, Khanal B, Singhi S. 2006. Clinico-laboratory profile and outcome of Japanese encephalitis in Nepali children. Ann Trop Paediatr 26:293301.[PubMed]
61. Basumatary LJ, Raja D, Bhuyan D, Das M, Goswami M, Kayal AK. 2013. Clinical and radiological spectrum of Japanese encephalitis. J Neurol Sci 325:1521.[PubMed]
62. Verma R. 2012. MRI features of Japanese encephalitis. BMJ Case Rep 2012(jul02 1):2012.[CrossRef] [PubMed]
63. Pradhan S, Pandey N, Shashank S, Gupta RK, Mathur A. 1999. Parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis. Neurology 53:17811786.[PubMed]
64. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, Jagsudee A, Saluzzo JF, Bhamarapravati N. 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66:264272.[PubMed]
65. Chaturvedi UC, Mathur A, Chandra A, Das SK, Tandon HO, Singh UK. 1980. Transplacental infection with Japanese encephalitis virus. J Infect Dis 141:712715.[PubMed]
66. Kumar R, Selvan AS, Sharma S, Mathur A, Misra PK, Singh GK, Kumar S, Arockiasamy J. 1994. Clinical predictors of Japanese encephalitis. Neuroepidemiology 13:97102.[PubMed]
67. Burke DS, Nisalak A, Lorsomrudee W, Ussery MA, Laorpongse T. 1985. Virus-specific antibody-producing cells in blood and cerebrospinal fluid in acute Japanese encephalitis. J Med Virol 17:283292.[PubMed]
68. Jacobson JA, Hills SL, Winkler JL, Mammen M, Thaisomboonsuk B, Marfin AA, Gibbons RV. 2007. Evaluation of three immunoglobulin M antibody capture enzyme-linked immunosorbent assays for diagnosis of Japanese encephalitis. Am J Trop Med Hyg 77:164168.[PubMed]
69. Khalakdina A, Shrestha SK, Malla S, Hills S, Thaisomboonsuk B, Shrestha B, Gibbons RV, Jacobson J. 2010. Field evaluation of commercial immunoglobulin M antibody capture ELISA diagnostic tests for the detection of Japanese encephalitis virus infection among encephalitis patients in Nepal. Int J Infect Dis 14(Suppl 3):e79e84.[PubMed]
70. Lewthwaite P, Shankar MV, Tio PH, Daly J, Last A, Ravikumar R, Desai A, Ravi V, Cardosa JM, Solomon T. 2010. Evaluation of two commercially available ELISAs for the diagnosis of Japanese encephalitis applied to field samples. Trop Med Int Health 15:811818.[PubMed]
71. Jelinek T, Cramer JP, Dieckmann S, Hatz C, Paulke-Korinek M, Alberer M, Reisinger EC, Costantini M, Gniel D, Bosse D, Lattanzi M. 2015. Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine. Travel Med Infect Dis 13:241250.[PubMed]
72. Tandan JB, Ohrr H, Sohn YM, Yoksan S, Ji M, Nam CM, Halstead SB. 2007. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com. Vaccine 25:50415045.[PubMed]
73. Appaiahgari MB, Vrati S. 2012. Clinical development of IMOJEV ®—a recombinant Japanese encephalitis chimeric vaccine (JE-CV). Expert Opin Biol Ther 12:12511263.[PubMed]
74. Solomon T, Dung NM, Wills B, Kneen R, Gainsborough M, Diet TV, Thuy TT, Loan HT, Khanh VC, Vaughn DW, White NJ, Farrar JJ. 2003. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 361:821826.[PubMed]
75. Hoke CH Jr, Vaughn DW, Nisalak A, Intralawan P, Poolsuppasit S, Jongsawas V, Titsyakorn U, Johnson RT. 1992. Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus. J Infect Dis 165:631637.[PubMed]
76. May FJ, Lobigs M, Lee E, Gendle DJ, Mackenzie JS, Broom AK, Conlan JV, Hall RA. 2006. Biological, antigenic and phylogenetic characterization of the flavivirus Alfuy. J Gen Virol 87:329337.[PubMed]
77. Mackenzie JS, Broom AK, Hall RA, Johansen CA, Lindsay MD, Phillips DA, Ritchie SA, Russell RC, Smith DW. 1998. Arboviruses in the Australian region, 1990 to 1998. Commun Dis Intell 22:93100.[PubMed]
78. Selvey LA, Dailey L, Lindsay M, Armstrong P, Tobin S, Koehler AP, Markey PG, Smith DW. 2014. The changing epidemiology of Murray Valley encephalitis in Australia: the 2011 outbreak and a review of the literature. PLoS Negl Trop Dis 8:e2656.[PubMed]
79. Robertson EG. 1952. Murray Valley encephalitis; pathological aspects. Med J Aust 1:107110.[PubMed]
80. Knox J, Cowan RU, Doyle JS, Ligtermoet MK, Archer JS, Burrow JN, Tong SY, Currie BJ, Mackenzie JS, Smith DW, Catton M, Moran RJ, Aboltins CA, Richards JS. 2012. Murray Valley encephalitis: a review of clinical features, diagnosis and treatment. Med J Aust 196:322326.[PubMed]
81. Burrow JN, Whelan PI, Kilburn CJ, Fisher DA, Currie BJ, Smith DW. 1998. Australian encephalitis in the Northern Territory: clinical and epidemiological features, 1987–1996. Aust N Z J Med 28:590596.[PubMed]
82. Lobigs M, Larena M, Alsharifi M, Lee E, Pavy M. 2009. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J Virol 83:24362445.[PubMed]
83. Ebel GD. 2010. Update on Powassan virus: emergence of a North American tick-borne flavivirus. Annu Rev Entomol 55:95110.[PubMed]
84. Gholam BI, Puksa S, Provias JP. 1999. Powassan encephalitis: a case report with neuropathology and literature review. CMAJ 161:14191422.[PubMed]
85. Centers for Disease Control and Prevention (CDC). 2001. Outbreak of Powassan encephalitis—Maine and Vermont, 1999–2001. MMWR Morb Mortal Wkly Rep 50:761764.[PubMed]
86. Hinten SR, Beckett GA, Gensheimer KF, Pritchard E, Courtney TM, Sears SD, Woytowicz JM, Preston DG, Smith RP Jr, Rand PW, Lacombe EH, Holman MS, Lubelczyk CB, Kelso PT, Beelen AP, Stobierski MG, Sotir MJ, Wong S, Ebel G, Kosoy O, Piesman J, Campbell GL, Marfin AA. 2008. Increased recognition of Powassan encephalitis in the United States, 1999–2005. Vector Borne Zoonotic Dis 8:733740.[PubMed]
87. Charrel RN, Lévy N, Tesh RB, Chandler LJ. 1999. Use of base excision sequence scanning for detection of genetic variations in St. Louis encephalitis virus isolates. J Clin Microbiol 37:19351940.[PubMed]
88. Kramer LD, Chandler LJ. 2001. Phylogenetic analysis of the envelope gene of St. Louis encephalitis virus. Arch Virol 146:23412355.[PubMed]
89. Venkat H, Krow-Lucal E, Hennessey M, Jones J, Adams L, Fischer M, Sylvester T, Levy C, Smith K, Plante L, Komatsu K, Staples JE, Hills S. 2015. Concurrent outbreaks of St. Louis encephalitis virus and West Nile virus disease—Arizona, 2015. MMWR Morb Mortal Wkly Rep 64:13491350.[PubMed]
90. Monath TP, Tsai TF. 1987. St. Louis encephalitis: lessons from the last decade. Am J Trop Med Hyg 37(Suppl):40S59S.[PubMed]
91. Day JF, Curtis GA. 1999. Blood feeding and oviposition by Culex nigripalpus (Diptera: Culicidae) before, during, and after a widespread St. Louis encephalitis virus epidemic in Florida. J Med Entomol 36:176181.[PubMed]
92. Rahal JJ, Anderson J, Rosenberg C, Reagan T, Thompson LL. 2004. Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study. J Infect Dis 190:10841087.[PubMed]
93. Gritsun TS, Frolova TV, Pogodina VV, Lashkevich VA, Venugopal K, Gould EA. 1993. Nucleotide and deduced amino acid sequence of the envelope gene of the Vasilchenko strain of TBE virus; comparison with other flaviviruses. Virus Res 27:201209.[PubMed]
94. Ecker M, Allison SL, Meixner T, Heinz FX. 1999. Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. J Gen Virol 80:179185.[PubMed]
95. Pogodina VV, Savinov AP. 1964. Variation in the pathogenicity of viruses of the tick-borne encephalitis complex for different animal species. I. Experimental infection of mice and hamsters. Acta Virol 8:424434.[PubMed]
96. McNeil JG, Lednar WM, Stansfield SK, Prier RE, Miller RN. 1985. Central European tick-borne encephalitis: assessment of risk for persons in the armed services and vacationers. J Infect Dis 152:650651.[PubMed]
97. Lukan M, Bullova E, Petko B. 2010. Climate warming and tick-borne encephalitis, Slovakia. Emerg Infect Dis 16:524526.[PubMed]
98. Gritsun TS, Lashkevich VA, Gould EA. 2003. Tick-borne encephalitis. Antiviral Res 57:129146.[PubMed]
99. Labuda M, Randolph SE. 1999. Survival strategy of tick-borne encephalitis virus: cellular basis and environmental determinants. Zentralbl Bakteriol 289:513524.[PubMed]
100. Isaeva MP, Leonova GN, Kozhemiako VB, Borisevich VG, Maĭstrovskaia OS, Rasskazov VA. 1998. [Apoptosis as a mechanism for the cytopathic action of tick-borne encephalitis virus]. Vopr Virusol 43:182186.[PubMed]
101. Ogawa M, Okubo H, Tsuji Y, Yasui N, Someda K. 1973. Chronic progressive encephalitis occurring 13 years after Russian spring-summer encephalitis. J Neurol Sci 19:363373.[PubMed]
102. Müller WK, Hilgenstock F, Kuip L, Leupe F. 1975. An uncommon case of amyotrophic lateral sclerosis with isolation of a virus from the CSF. J Neurol 211:1123.[PubMed]
103. Logar M, Bogovic P, Cerar D, Avsic-Zupanc T, Strle F. 2006. Tick-borne encephalitis in Slovenia from 2000 to 2004: comparison of the course in adult and elderly patients. Wien Klin Wochenschr 118:702707.[PubMed]
104. Nash D, Mostashari F, Fine A, Miller J, O'Leary D, Murray K, Huang A, Rosenberg A, Greenberg A, Sherman M, Wong S, Layton M 1999 West Nile Outbreak Response Working Group. 2001. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 344:18071814.[PubMed]
105. May FJ, Davis CT, Tesh RB, Barrett AD. 2011. Phylogeography of West Nile virus: from the cradle of evolution in Africa to Eurasia, Australia, and the Americas. J Virol 85:29642974.[PubMed]
106. Bondre VP, Jadi RS, Mishra AC, Yergolkar PN, Arankalle VA. 2007. West Nile virus isolates from India: evidence for a distinct genetic lineage. J Gen Virol 88:875884.[PubMed]
107. Brault AC, Huang CY, Langevin SA, Kinney RM, Bowen RA, Ramey WN, Panella NA, Holmes EC, Powers AM, Miller BR. 2007. A single positively selected West Nile viral mutation confers increased virogenesis in American crows. Nat Genet 39:11621166.[PubMed]
108. Ebel GD, Carricaburu J, Young D, Bernard KA, Kramer LD. 2004. Genetic and phenotypic variation of West Nile virus in New York, 2000–2003. Am J Trop Med Hyg 71:493500.[PubMed]
109. Kilpatrick AM, Meola MA, Moudy RM, Kramer LD. 2008. Temperature, viral genetics, and the transmission of West Nile virus by Culex pipiens mosquitoes. PLoS Pathog 4:e1000092.[PubMed]
110. Zaayman D, Venter M. 2012. West Nile virus neurologic disease in humans, South Africa, September 2008–may 2009. Emerg Infect Dis 18:20512054.[PubMed]
111. Bakonyi T, Ferenczi E, Erdélyi K, Kutasi O, Csörgő T, Seidel B, Weissenböck H, Brugger K, Bán E, Nowotny N. 2013. Explosive spread of a neuroinvasive lineage 2 West Nile virus in Central Europe, 2008/2009. Vet Microbiol 165:6170.[PubMed]
112. Papa A, Papadopoulou E, Gavana E, Kalaitzopoulou S, Mourelatos S. 2013. Detection of West Nile virus lineage 2 in Culex mosquitoes, Greece, 2012. Vector Borne Zoonotic Dis 13:682684.[PubMed]
113. Barzon L, Papa A, Pacenti M, Franchin E, Lavezzo E, Squarzon L, Masi G, Martello T, Testa T, Cusinato R, Palù G. 2013. Genome sequencing of West Nile virus from human cases in Greece, 2012. Viruses 5:23112319.[PubMed]
114. Komar N, Langevin S, Hinten S, Nemeth N, Edwards E, Hettler D, Davis B, Bowen R, Bunning M. 2003. Experimental infection of North American birds with the New York 1999 strain of West Nile virus. Emerg Infect Dis 9:311322.[PubMed]
115. Malkinson M, Banet C, Weisman Y, Pokamunski S, King R, Drouet MT, Deubel V. 2002. Introduction of West Nile virus in the Middle East by migrating white storks. Emerg Infect Dis 8:392397.[PubMed]
116. LaDeau SL, Kilpatrick AM, Marra PP. 2007. West Nile virus emergence and large-scale declines of North American bird populations. Nature 447:710713.[PubMed]
117. Salazar P, Traub-Dargatz JL, Morley PS, Wilmot DD, Steffen DJ, Cunningham WE, Salman MD. 2004. Outcome of equids with clinical signs of West Nile virus infection and factors associated with death. J Am Vet Med Assoc 225:267274.[PubMed]
118. Corwin A. , et al. 1993. Community-based prevalence profile of arboviral, rickettsial, and Hantaan-like viral antibody in the Nile River Delta of Egypt. Am J Trop Med Hyg 48:776783.[PubMed]
119. Hubálek Z, Halouzka J. 1999. West Nile fever—a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis 5:643650.[PubMed]
120. Lanciotti RS, Ebel GD, Deubel V, Kerst AJ, Murri S, Meyer R, Bowen M, McKinney N, Morrill WE, Crabtree MB, Kramer LD, Roehrig JT. 2002. Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East. Virology 298:96105.[PubMed]
121. Brault AC, Langevin SA, Bowen RA, Panella NA, Biggerstaff BJ, Miller BR, Komar N. 2004. Differential virulence of West Nile strains for American crows. Emerg Infect Dis 10:21612168.[PubMed]
122. Mackenzie JS, Gubler DJ, Petersen LR. 2004. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10(Suppl):S98S109.[PubMed]
123. Lindsey NP, Kuhn S, Campbell GL, Hayes EB. 2008. West Nile virus neuroinvasive disease incidence in the United States, 2002–2006. Vector Borne Zoonotic Dis 8:3539.[PubMed]
124. Petersen LR, Brault AC, Nasci RS. 2013. West Nile virus: review of the literature. JAMA.[PubMed]
125. Busch MP, Wright DJ, Custer B, Tobler LH, Stramer SL, Kleinman SH, Prince HE, Bianco C, Foster G, Petersen LR, Nemo G, Glynn SA. 2006. West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg Infect Dis 12:395402.[PubMed]
126. Carson PJ, Borchardt SM, Custer B, Prince HE, Dunn-Williams J, Winkelman V, Tobler L, Biggerstaff BJ, Lanciotti R, Petersen LR, Busch MP. 2012. Neuroinvasive disease and West Nile virus infection, North Dakota, USA, 1999–2008. Emerg Infect Dis 18:684686.[PubMed]
127. Mostashari F, Bunning ML, Kitsutani PT, Singer DA, Nash D, Cooper MJ, Katz N, Liljebjelke KA, Biggerstaff BJ, Fine AD, Layton MC, Mullin SM, Johnson AJ, Martin DA, Hayes EB, Campbell GL. 2001. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 358:261264.[PubMed]
128. Tsai TF, Popovici F, Cernescu C, Campbell GL, Nedelcu NI. 1998. West Nile encephalitis epidemic in southeastern Romania. Lancet 352:767771.[PubMed]
129. Mandalakas AM, Kippes C, Sedransk J, Kile JR, Garg A, McLeod J, Berry RL, Marfin AA. 2005. West Nile virus epidemic, northeast Ohio, 2002. Emerg Infect Dis 11:17741777.[PubMed]
130. Orton SL, Stramer SL, Dodd RY. 2006. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion 46:272277.[PubMed]
131. Kleinman S, Glynn SA, Busch M, Todd D, Powell L, Pietrelli L, Nemo G, Schreiber G, Bianco C, Katz L NHLBI Retrovirus Epidemiology Study (REDS). 2005. The 2003 West Nile virus United States epidemic: the America's Blood Centers experience. Transfusion 45:469479.[PubMed]
132. Lindsey NP, Staples JE, Lehman JA, Fischer M Centers for Disease Control and Prevention. 2010. Surveillance for human West Nile virus disease—United States, 1999–2008. MMWR Morb Mortal Wkly Rep Surveillance Summaries 59:117.
133. Lindsey NP, Staples JE, Lehman JA, Fischer M. 2012. Medical risk factors for severe West Nile Virus disease, United States, 2008–2010. Am J Trop Med Hyg 87:179184.[PubMed]
134. Murray K, Baraniuk S, Resnick M, Arafat R, Kilborn C, Cain K, Shallenberger R, York TL, Martinez D, Hellums JS, Hellums D, Malkoff M, Elgawley N, McNeely W, Khuwaja SA, Tesh RB. 2006. Risk factors for encephalitis and death from West Nile virus infection. Epidemiol Infect 134:13251332.[PubMed]
135. Bode AV, Sejvar JJ, Pape WJ, Campbell GL, Marfin AA. 2006. West Nile virus disease: a descriptive study of 228 patients hospitalized in a 4-county region of Colorado in 2003. Clin Infect Dis 42:12341240.[PubMed]
136. Cho H, Diamond MS. 2012. Immune responses to West Nile virus infection in the central nervous system. Viruses 4:38123830.[PubMed]
137. Nett RJ, Kuehnert MJ, Ison MG, Orlowski JP, Fischer M, Staples JE. 2012. Current practices and evaluation of screening solid organ donors for West Nile virus. Transpl Infect Dis 14:268277.[PubMed]
138. Freifeld AG, Meza J, Schweitzer B, Shafer L, Kalil AC, Sambol AR. 2010. Seroprevalence of West Nile virus infection in solid organ transplant recipients. Transpl Infect Dis 12:120126[CrossRef].[PubMed]
139. Kumar D, Drebot MA, Wong SJ, Lim G, Artsob H, Buck P, Humar A. 2004. A seroprevalence study of west nile virus infection in solid organ transplant recipients. Am J Transplant 4:18831888.[PubMed]
140. Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, Stramer SL, Stobierski MG, Signs K, Newman B, Kapoor H, Goodman JL, Chamberland ME West Nile Virus Transmission Investigation Team. 2003. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 349:12361245.[PubMed]
141. Centers for Disease Control and Prevention (CDC). 2002. Intrauterine West Nile virus infection—New York, 2002. MMWR Morb Mortal Wkly Rep 51:11351136.[PubMed]
142. O'Leary DR, Kuhn S, Kniss KL, Hinckley AF, Rasmussen SA, Pape WJ, Kightlinger LK, Beecham BD, Miller TK, Neitzel DF, Michaels SR, Campbell GL, Lanciotti RS, Hayes EB. 2006. Birth outcomes following West Nile Virus infection of pregnant women in the United States: 2003–2004. Pediatrics 117:e537e545.[PubMed]
143. Petersen LR, Hayes EB. 2008. West Nile virus in the Americas. Med Clin North Am 92:13071322, ix.[PubMed]
144. Lim PY, Behr MJ, Chadwick CM, Shi PY, Bernard KA. 2011. Keratinocytes are cell targets of West Nile virus in vivo. J Virol 85:51975201.[PubMed]
145. Schneider BS, Higgs S. 2008. The enhancement of arbovirus transmission and disease by mosquito saliva is associated with modulation of the host immune response. Trans R Soc Trop Med Hyg 102:400408.[PubMed]
146. Southam CM, Moore AE. 1954. Induced virus infections in man by the Egypt isolates of West Nile virus. Am J Trop Med Hyg 3:1950.[PubMed]
147. Guarner J, Shieh WJ, Hunter S, Paddock CD, Morken T, Campbell GL, Marfin AA,